Samuel Isaly (Trades, Portfolio), manager of Eaton Vance Worldwide Health Sciences Fund, was an active investor in health care-related stocks long before government became involved in the sector. His transactions in the first quarter, ended Feb. 29, reflected that interest.
Isaly sold his 631,200-share stake in Health Net Inc. (HNT, Financial), a Los Angeles-based health care insurance provider, for an average price of $64.87 per share. The transaction had a -2.35% impact on Isaly’s portfolio.
Health Net’s leading shareholder among the gurus is Jim Simons (Trades, Portfolio) with a stake of 1,047,600 shares. The stake is 1.35% of Health Net’s outstanding shares and 0.16% of Simons’ total assets.
Health Net has a P/E of 28.4, a forward P/E of 14.7, a P/B of 2.8 and a P/S of 0.3. GuruFocus gives Health Net a Financial Strength rating of 6/10 and a Profitability and Growth rating of 7/10.
Health Net sold for $67.19 per share Wednesday.
Isaly sold his 548,000-share stake in Mylan NV (MYL, Financial), a pharmaceuticals company based in White Sulphur Springs, West Virginia, for an average price of $50.8 per share. The divestiture had a -1.66% impact on his portfolio.
Vanguard Health Care Fund (Trades, Portfolio) is Mylan’s leading shareholder among the gurus with a stake of 24,253,075 shares. The stake is 4.94% of Mylan’s outstanding shares and 2.61% of Vanguard’s total assets.
Mylan has a P/E of 26.8, a forward P/E of 8, a P/B of 2.3 and a P/S of 2.4. GuruFocus gives Mylan a Financial Strength rating of 7/10 and a Profitability and Growth rating of 8/10.
Mylan sold for $44.48 per share Wednesday.
Isaly sold his 258,500-share stake in Molina Healthcare Inc. (MOH, Financial), a managed care company based in Long Beach, California, for an average price of $57.91 per share. The deal had a -0.92% impact on Isaly’s portfolio.
Simons is Molina’s leading shareholder among the gurus with a stake of 1,048,578 shares. The stake is 1.87% of Molina’s outstanding shares and 0.14% of Simons’ total assets.
Molina has a P/E of 25.5, a forward P/E of 14.5, a P/B of 2.3 and a P/S of 0.2. GuruFocus gives Molina a Financial Strength of 7/10 and a Profitability and Growth rating of 8/10.
Molina sold for $65.22 per share Wednesday.
Isaly sold his 241,779-share stake in Sawai Pharmaceutical Co. Ltd. (TSE:4555, Financial), a Japanese generic drug manufacturer, for an average price of ¥66.26 (60 cents in U.S. currency) per share. The divestiture had a -0.82% impact on Isaly’s portfolio.
Sawai’s leading shareholder among the gurus is Wasatch International Growth (Trades, Portfolio) with a stake of 174,894 shares. The stake is 0.48% of Sawai’s outstanding shares and 0.88% of Wasatch’s total assets.
Sawai has a P/E of 16.3, a P/B of 2.2 and a P/S of 2.3. GuruFocus gives Sawai a Financial Strength rating of 9/10 and a Profitability and Growth rating of 7/10.
Sawai’s price has gone up 10,827% since Isaly sold his stake. Sawai sold for ¥7,240 ($65.17 in American dollars) per share Wednesday.
Isaly slashed his stake in Novartis AG (NVS, Financial), a Swiss pharmaceutical company, by nearly 49% with the sale of 437,300 shares for an average price of $80.56 per share. The transaction had a -2.2% impact on Isaly’s portfolio.
The remaining stake of 457,700 shares is 0.02% of Novartis’ outstanding shares and 2.46% of Isaly’s total assets. Novartis’ leading shareholder among the gurus is Dodge & Cox with a stake of 45,107,085 shares. The stake is 1.89% of Novartis’ outstanding shares and 3.81% of Dodge & Cox’s total assets.
Novartis has a P/E of 27.6, a forward P/E of 15.1, a P/B of 2.5 and a P/S of 3.7. GuruFocus gives Novartis a Financial Strength rating of 8/10 and a Profitability and Growth rating of 5/10.
Novartis sold for $76.98 per share Wednesday.
Isaly trimmed his stake in Bristol-Myers Squibb Company (BMY, Financial), a New York-based pharmaceutical company, by almost 23%. The guru sold 303,300 shares for an average price of $64.87 per share. The deal had a -1.27% impact on Isaly’s portfolio.
The remaining stake of 1,029,700 shares is 0.06% of Bristol-Myers Squibb’s outstanding shares and 4.82% of Isaly’s total assets. Vanguard Health Care Fund (Trades, Portfolio) is Bristol-Myers Squibb’s leading shareholder among the gurus with a stake of 46,232,449 shares. The stake is 2.77% of Bristol-Myers Squibb’s outstanding shares and 6.32% of Vanguard’s total assets.
Bristol-Myers Squibb has a P/E of 75.7, a forward P/E of 24.4, a P/B of 8.2 and a P/S of 7.2. GuruFocus gives Bristol-Myers Squibb a Financial Strength rating of 8/10 and a Profitability and Growth rating of 5/10.
Bristol-Myers Squibb sold for $70.23 per share Wednesday.
Isaly cut his stake in Actelion Ltd. (XSWX:ATLN, Financial), a Swiss pharmaceutical company, by more than 43%. The guru sold 123,000 shares for an average price of CHF134.71 ($138.25 in U.S. money) per share. The transaction had a -1.02% impact on Isaly’s portfolio.
The remaining stake of 160,000 shares is 0.15% of Actelion’s outstanding shares and 1.68% of Isaly’s total assets. Actelion’s leading shareholder among the gurus is Vanguard Health Care Fund (Trades, Portfolio) with a stake of 2,632,318 shares. The stake is 2.51% of Actelion’s outstanding shares and 0.73% of Vanguard’s total assets.
Actelion has a P/E of 31.7, a forward P/E of 21.6, a P/B of 12.4 and a P/S of 8.6. GuruFocus gives Actelion a Financial Strength rating of 8/10 and a Profitability and Growth rating of 8/10.
Actelion sold for CHF155.5 ($159.58 in American currency) per share Tuesday.
Isaly trimmed his stake in Amgen Inc. (AMGN, Financial), a biopharmaceutical company based in Thousand Oaks, California, by more than 23%. The guru sold 93,000 shares for an average price of $153.93 per share. The deal had a -0.88% impact on Isaly’s portfolio.
The remaining stake of 303,000 shares is 0.04% of Amgen’s outstanding shares and 3.26% of Isaly’s total assets. Amgen’s leading shareholder among the gurus is PRIMECAP Management (Trades, Portfolio) with a stake of 29,177,226 shares. The stake is 3.88% of Amgen’s outstanding shares and 4.84% of PRIMECAP’s total assets.
Amgen has a P/E of 17.9, a forward P/E of 13.2, a P/B of 4.4 and a P/S of 5.8. GuruFocus gives Amgen a Financial Strength rating of 7/10 and a Profitability and Growth rating of 9/10.
Amgen sold for $161 per share Wednesday.
Isaly boosted his stake in WellCare Health Plans Inc. (WCG, Financial), a managed health care company based in Tampa, Florida, by nearly 148%. Isaly acquired 220,000 shares for an average price of $78.99 per share. The transaction had a 1.5% impact on Isaly’s portfolio.
The stake, now 369,000 shares, is 0.84% of WellCare’s outstanding shares and 2.51% of Isaly’s total assets. Alan Fournier (Trades, Portfolio) is WellCare’s leading shareholder among the gurus with a stake of 1,743,556 shares. The stake is 3.95% of WellCare’s outstanding shares and 3.64% of Fournier’s total assets.
WellCare has a P/E of 35.1, a forward P/E of 17.9, a P/B of 2.4 and a P/S of 0.3. GuruFocus gives WellCare a Financial Strength rating of 8/10 and a Profitability and Growth rating of 7/10.
WellCare sold for $93.64 per share Wednesday.
Isaly raised his stake in Regeneron Pharmaceuticals Inc. (REGN), a Tarrytown, New York-based biotechnology company, by more than 23%. Isaly purchased 26,000 shares for an average price of $473.62 per share. The acquisition had a 0.76% impact on Isaly’s portfolio.
The stake, now 137,000 shares, is 0.13% of Regeneron’s outstanding shares and 3.98% of Isaly’s total assets. Regeneron’s leading shareholder among the gurus is Frank Sands (Trades, Portfolio) with a stake of 3,698,553 shares. The stake is 3.53% of Regeneron’s outstanding shares and 5.64% of Sands’ total assets.
Regeneron has a P/E of 70.8, a forward P/E of 23.8, a P/B of 11.2 and a P/S of 11. GuruFocus gives Regeneron a Financial Strength rating of 7/10 and a Profitability and Growth rating of 6/10.
Regeneron sold for $390.28 per share Wednesday.
Isaly purchased a 162,000-share stake in Vertex Pharmaceuticals Inc. (VRTX), a pharmaceutical company based in Boston, for an average price of $104.94 per share. The deal had a 1.05% impact on Isaly’s portfolio.
The stake is 0.07% of Vertex’s outstanding shares and 1.05% of Isaly’s total assets. Vanguard Health Care Fund (Trades, Portfolio) is Vertex’s leading shareholder among the gurus with a stake of 9,827,411 shares. The stake is 3.99% of Vertex’s outstanding shares and 2.46% of Vanguard’s total assets.
Vertex has a forward P/E of 16.8, a P/B of 22.1 and a P/S of 19.7. GuruFocus gives Vertex a Financial Strength rating of 7/10 and a Profitability and Growth rating of 5/10.
Vertex sold for $84.5 per share Wednesday.
To view the portfolios of more gurus, visit the List of Gurus page. Not a premium member of GuruFocus? Try it free for seven days.
